NAD+ IV drips: separating the hype from the human data

What's this video probably claiming?

Based on the caption and hashtag context, this creator is almost certainly pitching NAD+ IV therapy as a direct route to better energy, sharper thinking, and accelerated cellular repair. The phrase "where your body needs it most" implies that intravenous delivery offers some kind of precision targeting that supplements or oral precursors can't match. The wellness-adjacent framing, "nourish your cells from the inside out," leans on the legitimate science around NAD+ biology while skipping over the parts that complicate the sales pitch. Expect the video to reference mitochondrial function, sirtuins, or DNA repair pathways without getting into what those mechanisms actually require to produce a measurable human outcome. IV drip clinics have been pushing this framing hard since roughly 2019, and the talking points have remained largely unchanged despite a more complicated evidence picture emerging since then.

What does the science actually show?

NAD+ is real and important. It's a coenzyme involved in redox reactions and is a substrate for enzymes like PARPs and sirtuins that do participate in DNA repair and metabolic regulation. NAD+ levels do appear to decline with age in animal models and in some human tissue assays. That part is not disputed. What is disputed is whether infusing NAD+ intravenously meaningfully raises intracellular NAD+ in the tissues that matter, and whether that translates to any clinical benefit in healthy adults. Camacho-Pereira et al. (2016, Cell Metabolism) showed NAD+ decline drives dysfunction in aged mice, but mice are not humans and IV NAD+ was not the intervention tested. Martens et al. (2023, Nature Aging) found that oral NMN supplementation at 600mg per day for 10 weeks improved muscle function in older men, but this used an oral NAD+ precursor, not IV NAD+ itself. The IV route bypasses gut metabolism but does not guarantee better cellular uptake.

Where does the social media noise diverge from clinical reality?

The gap here is significant. First, there are no published randomized controlled trials in healthy adults demonstrating that IV NAD+ infusions produce measurable improvements in energy, mental clarity, or cellular repair markers at doses typically used in clinic settings, which generally range from 250mg to 1000mg per session. Second, the "direct to cells" framing is misleading. NAD+ does not cross cell membranes freely. It is broken down extracellularly and then reassembled inside cells via salvage pathways, which means the delivery mechanism matters far less than the marketing implies. Third, the existing human clinical data on IV NAD+ is largely confined to addiction medicine contexts, specifically Shiling et al. and related protocols, not healthy optimization populations. The social media version of this therapy is running well ahead of the clinical version, and clinics charging several hundred dollars per infusion are monetizing that gap directly.

What should you actually know?

If you're considering NAD+ therapy, a few things are worth knowing before you book a drip. Side effects during IV NAD+ infusions are not rare. Chest tightness, nausea, and flushing are commonly reported during infusion, often requiring dose reduction or slower infusion rates. These are not trivial. The cost-to-evidence ratio is poor. Sessions typically run $200 to $600 each, and repeat infusions are standard protocol at most clinics, meaning costs compound quickly against a background of limited outcome data. Oral NAD+ precursors like NMN and NR have more human trial data behind them at this point, though effect sizes are modest. Airhart et al. (2017, PLOS ONE) showed NR at 1000mg per day raised whole blood NAD+ by roughly 2.7-fold over 6 weeks in healthy adults without significant adverse events. If cellular NAD+ support is the goal, the oral route has more evidence and far less risk than IV infusions currently do.